| Dr Elvin M Mendez, MD | |
|
22655 Bayshore Rd, Ste 130, Port Charlotte, FL 33980-2005 | |
| (941) 255-3722 | |
| (941) 255-3723 |
| Full Name | Dr Elvin M Mendez |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 38 Years |
| Location | 22655 Bayshore Rd, Port Charlotte, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003800939 | NPI | - | NPPES |
| 47861 | Other | FL | BCBS |
| 014287900 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | ME64431 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lee Memorial Health System | 8729996608 | 1022 |
News Archive
Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate).
Insurers sometimes cherry-pick facts to make their case against certain aspects of reform efforts, including a public plan, The Washington Post reports.
In a groundbreaking study that provides scientists with a critical new understanding of stem cell development and its role in disease, UCLA researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research led by Dr. Kathrin Plath, professor of biological chemistry, have established a first-of-its-kind methodology that defines the unique stages by which specialized cells are reprogrammed into stem cells that resemble those found in the embryo.
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.
Genetic screening of cancer can help doctors customize treatments so that patients with melanoma have the best chance of beating it, according to the results of a clinical trial by researchers at the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter.
› Verified 6 days ago
| Entity Name | Lee Memorial Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992873319 PECOS PAC ID: 8729996608 Enrollment ID: O20031118000604 |
News Archive
Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate).
Insurers sometimes cherry-pick facts to make their case against certain aspects of reform efforts, including a public plan, The Washington Post reports.
In a groundbreaking study that provides scientists with a critical new understanding of stem cell development and its role in disease, UCLA researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research led by Dr. Kathrin Plath, professor of biological chemistry, have established a first-of-its-kind methodology that defines the unique stages by which specialized cells are reprogrammed into stem cells that resemble those found in the embryo.
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.
Genetic screening of cancer can help doctors customize treatments so that patients with melanoma have the best chance of beating it, according to the results of a clinical trial by researchers at the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Elvin M Mendez, MD Po Box 2147, Fort Myers, FL 33902-2147 Ph: (941) 255-3722 | Dr Elvin M Mendez, MD 22655 Bayshore Rd, Ste 130, Port Charlotte, FL 33980-2005 Ph: (941) 255-3722 |
News Archive
Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate).
Insurers sometimes cherry-pick facts to make their case against certain aspects of reform efforts, including a public plan, The Washington Post reports.
In a groundbreaking study that provides scientists with a critical new understanding of stem cell development and its role in disease, UCLA researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research led by Dr. Kathrin Plath, professor of biological chemistry, have established a first-of-its-kind methodology that defines the unique stages by which specialized cells are reprogrammed into stem cells that resemble those found in the embryo.
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.
Genetic screening of cancer can help doctors customize treatments so that patients with melanoma have the best chance of beating it, according to the results of a clinical trial by researchers at the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter.
› Verified 6 days ago
Mrs. Usha Chandrahasa, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 3400 Tamiami Trl, Ste 201, Port Charlotte, FL 33952 Phone: 941-743-2277 Fax: 941-743-2275 |